Finerenone in Cardiorenal Disease: A Narrative Review of Molecular Mechanisms, Clinical Evidence, and Emerging Therapeutic Roles - PubMed
3 hours ago
- #Finerenone
- #Clinical Trials
- #Cardiorenal Disease
- Finerenone is a non-steroidal selective mineralocorticoid receptor (MR) antagonist with potent anti-inflammatory and antifibrotic activity.
- Clinical trials (FIDELIO-DKD, FIGARO-DKD, FINEARTS-HF) show finerenone reduces kidney disease progression and cardiovascular events in patients with type 2 diabetes and chronic kidney disease, including heart failure.
- Finerenone has a favorable safety profile with infrequent hyperkalemia when monitored, and its efficacy is preserved when combined with SGLT2 inhibitors.